MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Drug-induced parkinsonism(DIP)"

  • 2023 International Congress

    Tramadol Induces Neuroinflammation, Mitochondrial Oxidative Stress, Neurotransmitters Dysbalanced and Produced Parkinson’s Disease Like Symptoms in Experimental Wistar Rats

    KHA. Aran (Moga, India)

    Objective: The current study is designed to evaluate the possible neurotoxic effects of tramadol in Wistar rats. Background: Parkinson’s disease (PD) is a chronic neurodegenerative…
  • 2023 International Congress

    Severe tacrolimus-induced parkinsonism after kidney transplantation

    N. Riemersma, D. Kremer, R. Prak, F. Huser, M. Vander Stouwe, C. Vroomen, S. Bakker (Groningen, Netherlands)

    Objective: To describe a kidney transplant recipient with severe tacrolimus-induced parkinsonism. Background: Kidney transplant recipients have to adhere to strict immunosuppressive regimens, which generally include…
  • 2023 International Congress

    Pharmacological Invivo and invitro potential of resveratrol in experimental rat models of Parkinson’s disease

    R. Kumar, A. Kanojia (Darbhanga, India)

    Objective: Aim of study was to elucidate the pharmacological Invivo and invitro effects and mechanisms of action ofRT in experimental models of PD. Background: The…
  • 2023 International Congress

    Role of nanoparticles of berberine on oxidative stress in nigrostriatal tissue and neurobehavioral characteristics in rotenone induced animal model of Parkinson’s disease

    R. Rajput, V. Sharma (New Delhi, India)

    Objective: The current study exemplified the therapeutic potential of solid lipid nanoparticles (SLN) of berberine (BE-SLN) against oxidative stress in nigrostriatal tissue and neurobehavioral characteristics…
  • 2023 International Congress

    Clinical Profile Of Drug-Induced Movement Disorders In Cipto Mangunkusumo Hospital, Indonesia

    V. Sutanto, D. Tunjungsari, A. Tiksnadi (Jakarta, Indonesia)

    Objective: We aimed to portray the clinical spectrum of Drug-induced movement disorders (DIMDs) in Cipto Mangunkusumo Hospital, Jakarta, Indonesia Background: DIMDs remain a significant burden…
  • 2023 International Congress

    Drug-induced Parkinsonism and nonmotor symptoms: a case of gustatory rhinorrhea

    S. Casanova, A. Cabral, M. Branco (Vila Nova Gaia, Portugal)

    Objective: We aim to emphasize the relevance of contemplating nonmotor symptoms as possible features of drug-induced parkinsonism, and the utmost importance of further investigation in…
  • 2023 International Congress

    Olfactory discrimination differentiate drug-induced parkinsonism and Parkinson’s disease

    IH. Kwak, JJ. Lee, MS. Kim, SY. Kang, HI. Ma, YE. Kim (Anyang-si, Republic of Korea)

    Objective: In this study, we evaluated detailed differential features of olfactory function in PD and DIP. Background: DIP is common but it is challenging to…
  • 2023 International Congress

    Functional Neuroimaging and Follow up trends in Drug induced movement disorders.

    V. Mathur, A. Shetty, H. Shah, V. Lele, P. Wadia (Jaipur, India)

    Objective: To analyse the role of presynaptic dopaminergic imaging (TRODAT/ F Dopa PET) scans to predict long-term outcomes in patients of new onset parkinsonian symptoms…
  • 2022 International Congress

    Medication safety in Parkinson’s disease patients: evaluation of recommendations for decision support in the national drug-disease interaction database

    JJ. de Jong, CCM. Stuijt, MME. Diesveld, T. van Laar, SD. Borgsteede (Groningen, Netherlands)

    Objective: Objective: Drug-disease interactions in Parkinson's disease patients can give rise to situations where a drug may have negative effects on both motor- and non-motor…
  • 2022 International Congress

    Covid vaccine induced parkinsonism and cognitive dysfunction

    R. Dhamija, P. Talwar, S. Kushwaha, K. Gowdar (Delhi, India)

    Objective: To describe movement disorder and cognitive impairment in two patients following COVID-19 vaccination. Background: The manifestation of neurological complications have been increasingly evidenced following…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 10
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley